Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression

Journal of the National Cancer Institute

Volumn 108, Issue 10, 2016, Pages

  Polley, Eric ^a   Kunkel, Mark ^b   Evans, David ^c   Silvers, Thomas ^b   Delosh, Rene ^b   Laudeman, Julie ^a   Ogle, Chad ^b   Reinhart, Russell ^b   Selby, Michael ^b   Connelly, John ^b   Harris, Erik ^c   Fer, Nicole ^b   Sonkin, Dmitriy ^b   Kaur, Gurmeet ^c   Monks, Anne ^a   Malik, Shakun ^a   Morris, Joel ^a   Teicher, Beverly A ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b Division of Cancer Treatment and Diagnosis   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; AZD 4547; DACTOLISIB; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEMCITABINE; ISOSORBIDE; LINSITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MOTESANIB; NAVITOCLAX; OBATOCLAX; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1; SOMATOMEDIN C RECEPTOR; TALAZOPARIB; TAMOXIFEN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VENETOCLAX; ABT-737; BCL2 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; CELL CYCLE PROTEIN; FGFR1 PROTEIN, HUMAN; IGF1R PROTEIN, HUMAN; KIF11 PROTEIN, HUMAN; KINESIN; MIRN140 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; MIRN92 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; NEW DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITROPHENOL; ONCOPROTEIN; PARP1 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN RECEPTOR; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CLINICAL ASSESSMENT; CONCENTRATION RESPONSE; DRUG APPROVAL; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; EXON; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOSIS; MOLECULAR BIOLOGY; NON SMALL CELL LUNG CANCER; ONCOLOGY; PRIORITY JOURNAL; SMALL CELL LUNG CANCER; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; GENE EXPRESSION; HUMANS; KINESIN; LUNG NEOPLASMS; MICRORNAS; NITROPHENOLS; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, SOMATOMEDIN; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84994238857     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw122     Document Type: Article

References (63)

1. Pietanza CM, Byers LA, Minna JD, Rudin CM. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21 (10): 2244-2255.
2. William WN, Glisson BS. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol. 2011;8 (8):611-619.
3. Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol. 2015;33 (3):306-312.
4. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012; 25 (Suppl 1):S18-S30.
5. Sarvi S, Mackinnon AC, Avlonitis N, et al. CD133 cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014;74 (5):1554-1565.
6. Meder L, Konig K, Ozretic L, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer. 2016;138 (4):927-938.
7. Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present and future. Curr Oncol Rep. 2010;12 (5):327-334.
8. D'Angelo SP, Pietanza MC. The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther. 2010;10 (1):1-10.
9. Johnson BE, Russell E, Simmons AM, et al. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem Suppl. 1996;24:210-217.
10. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463 (7278):184-192.
11. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44 (10):1111-1116.
12. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small cell lung cancer. Nat Genet. 2012;44 (10):1104-1110.
13. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524 (7563):47-53.
14. Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33 (9):1000-1007.
15. Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. 2014;111 (41):14788-14793.
16. Castro DS, Martynoga B, Parras C, et al. A novel function of the proneural factor Ascl1 in progenitor proliferation identified by genome-wide characterization of its targets. Genes Dev. 2011;25 (9):930-945.
17. Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res. 2008;14 (11):3268-3277.
18. Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18 (11):3163-3169.
19. Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN673 in small cell lung cancer. Clin Cancer Res. 2013;19 (22):6322-6328.
20. Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2 (9):798-811.
21. Coe BP, Thu KL, Aviel-Ronen S, et al. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. Plos One. 2013;8 (8):e71670.
22. Lonial S, Delforge M, Einsele H, et al. The AFFIRM study: a mutlicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma. J Clin Oncol. 2015;33 (Suppl):Abstr TPS8613.
23. Zonder JA, Raje NS, Scott EC, et al. A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma. J Clin Oncol. 2015;33 (Suppl):Abstr TPS8612.
24. Mross KB, Scharr D, Richly H, et al. First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein. J Clin Oncol. 2014; 32 (Suppl):Abstr 2564.
25. Rath O, Kozielski F. Kinesins and cancer. Nat Rev Cancer. 2012;12 (8):527-539.
26. Vicente JJ, Wordeman L. Mitosis, microtubule dynamics and the evolution of kinesins. Exp Cell Res. 2015;334 (1):61-69.
27. Holen K, DiPaola R, Liu G, et al. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012; 30 (3):1088-1095.
28. Matsumura Y, Umemura S, Ishii G, et al. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. J Cancer Res Clin Oncol. 2015;141 (12):2159-2170.
29. Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A. 2012;109 (42):17034-17039.
30. Badzio A, Wynes MW, Dziadziuszko R, et al. Increased insulin-like growth factor 1 receptor (IGF1R) protein expression and gene copy number in small cell lung cancer. J Thorac Oncol. 2010;5 (12):1905-1911.
31. Walls M, Baxi SM, Mehta Liu KKC, et al. Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216. Clin Cancer Res. 2014;20 (3):631-643.
32. Lee JH, Voortman J, Dingemans AMC, et al. MicroRNA expression and clinical outcome of small cell lung cancer. Plos One. 2011;6 (6): e21300.
33. Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12 (9):1221-1239.
34. Zhang W, Dolan ME. Emerging role of microRNAs in drug response. Curr Opin Mol Ther. 2010;12 (6):695-702.
35. Gazdar AF, Gao B, Minna JD. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer. 2010;68 (3):309-318.
36. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20 (8):897-903.
37. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line data base. J Cell Biochem Suppl. 1996;24:32-91.
38. Bengtsson H, Simpson K, Bullard J, Hansen K. aroma. affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory, Tech Report #745, Department of Statistics, University of California, Berkeley, February 2008. http://statistics. berkeley. edu/tech-re ports/745.
39. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomolec Screen. 1999;4 (2):67-73.
40. Kai M, Kanaya N, Wu SV, et al. Targeting breast cancer stem cells in triple negative breast cancer using a combination of LBH589 and salinomycin. Breast Cancer Res Treat. 2015;151 (2):281-294.
41. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nature Rev Drug Discov. 2008;7 (12):989-1000.
42. Antonia SJ, Bendell JC, Taylor MH, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33 (Suppl):Abstr 7503.
43. Ott PA, Fernandez MEE, Hiret S, et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. J Clin Oncol. 2015;33 (Suppl):Abstr 7502.
44. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 2007;67 (3):1176-1183.
45. Vogler M, Weber K, Dinsdale D, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009;16 (7):1030-1039.
46. Vogler M. Targeting BCL2-proteins for the treatment of solid tumors. Adv Med. 2014;2014:943648.
47. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature. 2005;435 (7042):677-681.
48. Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68 (7): 2321-2328.
49. Gandhi L, Camidge DR, Ribeiro de Oliveira M, et al. Phase 1 study of navitoclax (ABT-263), a novel BCL-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29 (7):909-916.
50. Wainberg ZA, Rafii S, Ramanathan RK, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. J Clin Oncol. 2014;32 (Suppl):Abstr 7522.
51. Tang SW, Bilke S, Cao L, et al. SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing's sarcoma. Clin Cancer Res. 2015; 21 (18):4184-4193.
52. Marinov M, Ziogas A, Pardo OE, et al. AKt/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res. 2009;15 (4):1277-1287
53. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized phase II trial of two levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007;2 (11):1036-1041.
54. Tarhini A, Kotsakis A, Gooding W, et al, Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010; 16 (23):5900-5907.
55. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer. 2008;60 (2):166-174.
56. Zinn RL, Gardner EE, Marchionni L, et al. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Molec Cancer Therap. 2013;12 (6):1131-1139.
57. Shah JJ, Cohen AD, Zonder JA, et al. Phase I trial of ARRY-520 in relapsed/ refractory multiple myeloma (RR MM). J Clin Oncol. 2010;28 (Suppl):Abstr 8132.
58. Chandrasekaran G, Tatrai P, Gergely F. Hitting the brakes: targeting microtubule motors in cancer. Brit J Cancer. 2015;113 (5):693-698.
59. Gandhi L, Chu QS, Stephenson J, et al. An open label phase II trial of the Plk1 inhibitor BI2536, in patients with sensitive relapse small cell lung cancer (SCLC). J Clin Oncol. 2009;27 (Suppl):Abstr 8108.
60. Melichar B, Adenis A, havel L, et al. Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE). J Clin Oncol. 2013;31 (Suppl):Abstr 605.
61. Sokilde R, Kaczkowski B, Podolska A, et al. Global microRNA analysis of the NCI-60 cancer cell panel. Molec Cancer Therap. 2011;10 (3):375-384.
62. Liu H, D'Andrade P, Fulmer-Smentek S, et al. mRNA amd microRNA expression profiles of the NCI-60 integrated with drug activities. Molec Cancer Therap. 2010;9 (5):1080-1091.
63. Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform. 2014;15 (4):648-659.